36836 Federal Register / Vol. 65, No. 113 / Monday, June 12, 2000 / Notices

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: National Cancer

Institute Board of Scientific Advisors.

Date: June 22, 2000.

Time: 8:30 AM to 6:00 PM.

Agenda: Report of the Director, NCI;

Ongoing and New Business, Special Initiative

Updates, Budget Presentation, and RFA

Concept Reviews.

Place: 900 Rockville, Pike, Building 31,

Conference Room 10, Bethesda, MD 20892.

Contact Person: Paulette S. Gray, PhD,

Executive Secretary, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Rm. 8141, Bethesda, MD 20892.

This notice is being published less than 15

days prior to the meeting due to scheduling

changes.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: June 2, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14747 Filed 6–9–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given to the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, National

Cooperative Drug Discovery Group.

Date: June 7–9, 2000.

Time: 7:00 PM to 5:00 PM

Agenda: To review and evaluate grant

applications.

Place: Gaithersburg Hilton, 620 Perry Park,

Gaithersburg, MD 20877.

Contact Person: C.M. Kerwin, PhD,

Scientific Review Administrator, Special

Review, Referral and Resources Branch,

Division of Extramural Activities, National

Cancer Institute, National Institutes of

Health, 6116 Executive Boulevard, Room

8086, Rockville, MD 20892–7405, 301/496–

7421.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: June 2, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14748 Filed 6–9–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Allergy and Infectious Diseases Special

Emphasis Panel.

Date: June 19, 2000.

Time: 1 pm to 4 pm.

Agenda: To review and evaluate contract

proposals.

Place: 6700B Rockledge Drive, Room 2148,

Bethesda, MD 20817. (Telephone Conference

Call)

Contract Person: Hagit S. David, PhD,

Scientific Review Administrator, Scientific

Review Program, Division of Extramural

Activities, NIAID, NIH, Room 2217, 6700–B

Rockledge Drive, MSC, 7610, Bethesda, MD

20892–7610, 301–496–2550.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.855, Allergy, Immunology,

and Transplantation Research; 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health, HHS)

Dated: June 2, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14746 Filed 6–9–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Antagonists of the αEβ7

Integrin as Therapeutic Agents for

Inflammatory Diseases

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. § 209 (c) (1) and 37 CFR

§ 404.7 (a) (1) (i), that the National

Institutes of Health, Department of

Health and Human Services is

contemplating the grant of an exclusive

license to practice the inventions

embodied in PCT Patent Application S/

N PCT/US99/27817 (filed November 23,

1999) based on U.S. Patent Application

60/109,957 (filed November 25, 1998),

entitled ‘‘Antagonists of the αEβ7

Integrin as Therapeutic Agents for

Inflammatory Diseases’’, to BioSeek,

Inc., having a place of business in San

Francisco, CA. The patent rights in

these inventions have been assigned to

the United States of America.

The prospective exclusive license

territory will be worldwide and the field

of use may be limited to αEβ7-related

human therapeutics for the treatment of

inflammatory diseases.

DATES: Only written comments and/or

license applications which are received

by the National Institutes of Health on

or before August 11, 2000 will be

considered.

ADDRESSES: Requests for copies of the

patent, inquiries, comments and other

materials relating to the contemplated

exclusive license should be directed to:

Vasant Gandhi, J.D., Ph.D., Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,